Dr. Ranjit Kumar Goudar, MD

Dr. Goudar practices at Virginia Oncology Associates in Norfolk, Virginia.

Dr. Goudar's NPI, 1467584383, was assigned on March 9, 2007. Dr. Goudar graduated from Duke University School of Medicine in 2004. Dr. Goudar holds Virginia license 0101246882.

Dr. Goudar's primary practice is Virginia Oncology Associates, at 6251 E Virginia Beach Blvd, Norfolk, VA 23502 in Norfolk City. The practice phone is (757) 466-8683.

Dr. Goudar's primary practice is Virginia Oncology Associates in Norfolk, Virginia. Dr. Goudar is also affiliated with Sentara Norfolk General Hospital. The medical group on file is Virginia Oncology Associates. Dmand AI also links Dr. Goudar to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Goudar practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Goudar's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Goudar's licenses on file in 2 states: Virginia and North Carolina.

CMS data shows 24,034 Medicare services from Dr. Goudar across 48 procedure codes in 2024, for 597 Medicare patients. Medicare paid $522,610 for them. Every service was in an office.

CMS counts 597 Medicare patients who saw Dr. Goudar in 2024. The largest group is 65 to 74, with 281 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.92, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Goudar's median patient age at 59, with 82% women.

In 2024, Dr. Goudar wrote 584 Medicare Part D claims for 97 patients. 79% of them were for generic drugs. CMS names the drug for 407 of them, across 18 drugs with 11 or more claims each, at $633,379 in total drug cost. In 2023, CMS named 560 claims across 20 drugs.

Dr. Goudar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Goudar as offering telehealth.

Dmand AI links 9 papers to Dr. Goudar, published from 2013 to 2024. 2013 was the busiest year, with 3. Dr. Goudar has published most often in Oncotarget. Dr. Goudar's most frequent co-authors are John P. Kirkpatrick, MD, Katherine Barnett Peters, MD, PhD and Armin Rashidi, MD.

CMS Open Payments shows 12 general payments to Dr. Goudar from 8 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 52% of the total. Pfizer Inc. paid the most, $181.

Dr. Goudar graduated from Duke University School of Medicine in 2004.